The initiation of coverage by Wells Fargo with an Equal-Weight rating suggests a neutral outlook on GeneDx Holdings. The price target of $34 provides a specific valuation expectation, but the neutral rating indicates no strong buy or sell recommendation, likely resulting in a stable short-term stock price.